Atlas Trials

A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

Clinical trial NCT02236000 · COMPLETED

Trial details

NCT number
NCT02236000
Sponsor
NSABP Foundation Inc
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2014-08-01
Primary completion
2020-12-01
Enrollment
49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.